Effect of ulinastatin on the expression of serum inflammatory mediators in patients with acute myocardial infarction (AMI) after thrombolysis
- VernacularTitle:乌司他丁对急性心肌梗死患者溶栓治疗后血清炎症介质的影响
- Author:
Linhui SHI
1
;
Zhouzhou DONG
;
Longqiang YE
;
Panpan LIU
Author Information
1. 宁波市医疗中心李惠利东部医院台北医学大学宁波医疗中心重症医学科
- Keywords:
Ulinastatin;
Acute myocardial infarction;
Thrombolysis;
Inflammatory mediator
- From:
China Modern Doctor
2018;56(15):117-120
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of ulinastatin on the expression of serum inflammatory mediators in pa tients with acute myocardial infarction (AMI) after thrombolysis. Methods 84 patients with AMIin our hospital from January 2017 to December 2017 were selected and randomly divided into the control group and the experimental group with 42 cases in each group. The control group received recombinant streptokinase intravenous thrombolytic therapy, while the experimental group was given intravenous infusion of ulinastatin in the foundation of thrombolytic therapy. Two groups of patients were extracted venous blood to measure the expression levels of inflammatory mediators including hs-CRP, IL-1, IL-10 and TNF-a before treatment, 24 h and 72 h after treatment. Results 24 h after treatment, the expression levels of hs-CRP, IL-1, IL-10 and TNF-a in the two groups were higher than those before the treatment, and the difference was statistically significant (P＜0. 05). However, the increase in the experimental group was lower than that of the control group (P＜0. 05). 72 h after treatment, the levels of inflammatory mediators in the two groups were significantly lower than those before and 24 h after the treatment(P＜0. 05). The decrease in the experimental group was higher than that of the control group and the difference between the two groups was statistically significant(P＜0. 05). There was no significant difference in the incidence of adverse reactions and adverse cardiovascular events between the two groups during hospitalization after thrombolysisP＞0. 05). Conclusion The use of ulinastatin before and after thrombolytic therapy can effectively inhibit the expression levels of inflammatory mediators and relieve myocardial ischemia reperfusion injury in patients with AMI.
